Satisfaction scores with types of change in biologic care and asthma control
| n (%) | Satisfaction with care | Satisfaction with changes in care | Effect on asthma control attributed to changes in biologic treatment | |
| All patients on biologics (n=709) | ||||
| No change | 542 (76) | 4.40±0.59# | ||
| Change | 167 (24) | 3.93±0.68# | 3.72±1.08 | 1.90±0.88 |
| Type of change reported (n=167) | ||||
| Switch to home administration | 153 (92) | 3.96±0.67 | 3.90±0.87 | 1.76±0.74 |
| Treatment less frequent | 4 (2) | 4.05±0.46 | 3.83±0.53 | 2.22±1.57 |
| Treatment postponed | 7 (4) | 3.63±0.84 | 3.92±1.02 | 2.05±0.83 |
| Treatment stopped | 3 (2) | 3.04±0.33 | 3.17±0.29 | 3.22±0.69 |
Data presented as mean±sd, unless otherwise stated. Patient-reported changes in biologic care during the coronavirus disease 2019 (COVID-19) pandemic and associated levels of satisfaction with care and changes in care, and patient-perceived effect on asthma control. Higher satisfaction scores indicate better satisfaction (range 1–5, 1=very low satisfaction and 5=very high satisfaction); higher asthma control scores indicate greater agreement with a statement that changes in biologic care induced worsening of asthma control (range 1–5, 1=strongly disagree and 5=strongly agree). Data of 709 patients on biologics; 26 did not complete the questions concerning satisfaction with care. #: t (674)=8.47, p<0.001, d=0.72.